

Amendments to the Claims

Following is a complete listing of the claims pending in the application, as amended:

1. (Original) A dosage form comprising

(a) a membrane defining a compartment, the membrane having an exit orifice formed or formable therein and at least a portion of the membrane being semipermeable;

(b) an expandable layer located within the compartment remote from the exit orifice and in fluid communication with the semipermeable portion of the membrane;

(c) a delay layer located adjacent the exit orifice;

(d) a drug layer located within the compartment between the delay layer and the expandable layer; and

(e) an interface boundary between the delay layer and the drug layer, the interface boundary being convex in shape relative to the exit orifice.

2. (Original) The dosage form of Claim 1 wherein the delay layer and the drug layer are formed by a compression sequence in which the delay layer is compressed into its form prior to the drug layer being compressed into its form.

3. (Original) The dosage form of Claim 1 wherein:

the delay layer exhibits a higher viscosity than the drug layer when both are subjected to the same level of hydration.

4. (Original) The dosage form of Claim 1 wherein:

the viscosity of the delay layer is higher than the viscosity of the drug layer at equivalent aqueous saturation levels.

5.-27. (Canceled)

28. (Currently amended) The dosage form of Claim 1 wherein the drug layer comprises a drug selected from the group of cyclobenzaprine, amitriptyline, imipramine and desipramine.

29. (Original) The dosage form of Claim 1 wherein the drug layer comprises cyclobenzaprine and that provides a cyclobenzaprine plasma concentration of 6 to 8 ng/ml three to four hours after dosing and approximately 8 to 12 ng/ml eighteen to twenty hours after oral administration in a human.

30.-39. (Canceled)